DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

Conditions: Esophageal Squamous Carcinoma; HER-2 Protein Overexpression Interventions: Drug: RC48+PD-1+platinum-based Sponsors: Changhai Hospital Not yet recruiting

https://clinicaltrials.gov/study/NCT06055153

Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials